Carvykti Surpasses $1 Billion in Annual Sales, Emerges as Blockbuster CAR-T Therapy from Legend Biotech and Janssen

　　【Pharmaceutical Network Product Information] Recently, Johnson & Johnson announced its Q3 2025 financial report, showing a 6.8% year-over-year increase in Q3 revenue to $24 billion; net profit surged 91.2% year-over-year to $5.1 billion. In the innovative pharmaceuticals business segment, sales of the BCMA CAR-T product Carvykti, developed in collaboration with Legend Biotech, showed significant growth, serving as one of the main drivers of sales growth.
 

According to the financial report, Carvykti's total sales in Q3 2025 increased by 83.5% year-over-year, reaching $524 million. Notably, Carvykti's sales this year have already surpassed $1 billion, with Q1 at $369 million, Q2 at $439 million, and Q3 at $524 million, totaling $1.332 billion.
 

Data shows that Carvykti, as a CAR-T therapy, was approved for marketing in February 2022. Its target is B-cell maturation antigen, a protein commonly found on B cells. Initially, Carvykti was used to treat patients with relapsed or refractory multiple myeloma who had previously received at least four lines of therapy. However, in April 2024, the U.S. Food and Drug Administration (FDA) approved its expanded use to second-line treatment.
 

It is reported that Johnson & Johnson and Legend Biotech have jointly invested $150 million in building new production facilities this year to propel the CAR-T therapy Carvykti toward blockbuster drug status ("blockbuster drug" refers to a marketed drug with annual sales exceeding $1 billion). The aim is to double Carvykti's production output. The engineering design work for this project has already commenced, with completion expected by 2028.
 

Industry insiders say that in the highly competitive biopharmaceutical field, CAR-T therapy has always been highly anticipated. The expansion of Carvykti not only demonstrates Johnson & Johnson and Legend Biotech's firm confidence in the future market potential of this drug but also reflects their ambitious layout in the multiple myeloma treatment market.
 

As the third-quarter report card was unveiled, Johnson & Johnson raised its full-year estimated revenue guidance to $93.7 billion, representing a midpoint growth of 5.7%. This quarter, Johnson & Johnson achieved significant breakthroughs in innovative drugs, which may expand the company’s growth expectations for the next few years. Among the developments, TREMFYA received FDA approval for a subcutaneous formulation for inflammatory bowel disease, becoming the first all-subcutaneous IL-23 regimen. TREMFYA’s sales this quarter reached $1.42 billion, a year-on-year increase of 41.3%. Additionally, Johnson & Johnson submitted a marketing application for icotrokinra for psoriasis treatment. Clinical data shows that this product outperformed deucravacitinib in head-to-head trials.
 

While issuing an optimistic earnings forecast, Johnson & Johnson plans to separate its slower-growing orthopedics business from the rest of the company within 18 to 24 months. Relevant sources indicate that the company is still evaluating how to divest the orthopedics unit.
 

Data shows that Johnson & Johnson's orthopedic business mainly produces hip, knee, and shoulder joint implants, surgical instruments, and other related products. In 2024, the revenue of this business is expected to be approximately $9.2 billion, accounting for about 10% of Johnson & Johnson's total revenue. This spin-off will also benefit Johnson & Johnson, allowing it to shift its product portfolio toward faster-growing and higher-margin markets.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.